CClinicalTrials.gg
CompletedNCT03433261Updated Dec 14, 2021

Ketogenic Diet for Reduction of CNS Oxygen Toxicity in Working Divers

An interventional study of Ketogenic Diet in CNS Oxygen Toxicity, Ketogenic Diet, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-14.

Sponsored by Duke University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this research study is to understand the effect of nutritional ketosis on CNS oxygen toxicity in undersea divers. The investigators hope this will provide a starting point to develop methods for improving the safety of Navy divers, warfighters and submariners.

Read the detailed description

Participants in the study will undergo a physical exam and testing as well as training on cognitive testing software as part of the screening process. Eligible subjects will be assigned a normal diet or a ketogenic diet (a diet high in fat/protein and low in carbohydrates) for three days before testing. Subjects will be immersed in water to the shoulders, inside a hyperbaric (high pressure) chamber while breathing 100% oxygen at increased atmospheric pressure, and doing cycling exercise. Testing on the cognitive software, as well as blood sampling and physical monitoring will be done while in the chamber. All tests and procedures will be completed again at least one week later with the diet not assigned for the first session.

02

Conditions studied

  • CNS Oxygen Toxicity, Ketogenic Diet

Browse trials for

03

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Males \& females between 18 and 50 years old
  • Able to pedal a bicycle ergometer continuously for 15 minutes
  • Non-smoker
  • No history of cardiovascular disease, including coronary artery disease, valvular disease, cardiomyopathy or hypertension.
  • No history of lung disease

Exclusion criteria

Exclusion Criteria:

  • Prolonged QTc on initial ECG
  • Currently pregnant or attempting to become pregnant.
  • Have a history of:

    1. Smoking
    2. Coronary artery disease
    3. Hypertension
    4. Seizures
    5. Exercise intolerance
    6. Psychiatric disorder
    7. Previous pneumothorax or pneumomediastinum
    8. Hypo or hyperglycemia
    9. Diabetes
  • Regularly take any medications which may alter heart rate, blood pressure, neurotransmitter function, mood or affect.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
91 participants (actual)

Study arms

  • No intervention
    Normal Diet

    The participant will eat their usual diet for at least 72 hrs prior to the experiment, document their diet during that time and be tested for ketone level immediately prior to the experiment.

  • Experimental
    Ketogenic Diet

    The participant will follow a ketogenic diet for 72 hrs prior to the experiment and consume a ketone supplement 60 minutes prior to the experiment. They will document their diet and be tested for ketone level immediately prior to the experiment.

    Dietary Supplement: Ketogenic Diet

Interventions

  • Dietary supplementKetogenic Diet

    Eat a ketogenic diet (low carbohydrate, high fat diet) for 72 hrs prior to the experiment and consume a dietary ketone supplement 60 minutes before the experiment.

05

What researchers measure

Primary outcomes

  1. Time to First Manifestations of CNS Oxygen Toxicity

    Time to the first manifestation of CNS Oxygen Toxicity: visual or hearing changes, nausea, twitching, irritability, dizziness, convulsions or change consistent with possible CNS Oxygen Toxicity.

    Time frame: 2 hrs

06

Study locations

1 site
  • Duke University Hospital
    Durham, North Carolina 27710, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03433261
Lead sponsor
Duke University
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Feb 14, 2018
Start date
Mar 1, 2018
Primary completion
Oct 30, 2021
Completion
Oct 30, 2021
Last update
Dec 14, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion